Q3 2020 13F Holders as of 30 Sep 2020
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
4,761,719
-
Share change
-
-498,742
-
Total reported value
-
$18,443,257
-
Put/Call ratio
-
35%
-
Price per share
-
$3.87
-
Number of holders
-
23
-
Value change
-
-$1,925,407
-
Number of buys
-
10
-
Number of sells
-
9
Institutional Holders of Protalix BioTherapeutics, Inc. - COM (PLX) as of Q3 2020
As of 30 Sep 2020,
Protalix BioTherapeutics, Inc. - COM (PLX) was held by
23 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
4,761,719 shares.
The largest 10 holders included
HIGHBRIDGE CAPITAL MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, Psagot Investment House Ltd., UBS OCONNOR LLC, BRIDGEWAY CAPITAL MANAGEMENT INC, Phoenix Holdings Ltd., BANK OF MONTREAL /CAN/, KENNEDY CAPITAL MANAGEMENT, INC., ETF MANAGERS GROUP, LLC, and CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM.
This page lists
23
institutional shareholders reporting positions in this security
for the Q3 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.